/PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug.
Investegate announcements from Galapagos NV, Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022
Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and remission
Investegate announcements from Galapagos NV, Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
Type II variation1 regulatory application to amend the European label of Jyseleca (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and rheumatic